TABLE 3.
Unadjusted Per Member Per Month Costs After Initiation of Treatment by Cumulative Duration of Buprenorphine/Methadone or Naltrexone Treatment Over 12 Months of Contiguous Enrollment
| Unadjusted Mean Cost Per Member Per Month [Mean (SD)] ($) | ||||
|---|---|---|---|---|
| Cumulative Duration on | n (%) | Baseline | Follow-up | Unadjusted Within Group Cost Ratio |
| Buprenorphine/methadone (d) | ||||
| 0 | 17,606 (83) | 3366 (7663) | 3360 (6132) | 1.00 |
| 1–30 | 738 (3.5) | 2094 (5363) | 3332 (5488) | 1.59 |
| 31–180 | 1127 (5.3) | 2037 (6608) | 2847 (5051) | 1.40 |
| >180 | 1729 (8.2) | 1356 (3256) | 1973 (2631) | 1.46 |
| Naltrexone (d) | ||||
| 0 | 19,900 (93.9) | 3104 (7407) | 3123 (5824) | 1.01 |
| 1–30 | 567 (2.7) | 2474 (4523) | 4361 (6136) | 1.76 |
| 31–180 | 574 (2.7) | 3116 (6321) | 4898 (6012) | 1.57 |
| >180 | 159 (0.8) | 3156 (5405) | 5023 (7129) | 1.59 |